Analysing data from patient medical records to investigate whether a 18FDG-PET scan can predict survival in patients with breast cancer that can be treated with surgery

Prognostic value of pre-treatment 18FDG-PET in operable breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN17962845

Enrollment

182

Registered

2020-05-12

Start date

2002-01-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Operable breast cancer. Cancer

Interventions

Records of patients with breast cancer who received pre-operative 18FDG-PET scans will be included. The records will be anonymised and the following types of data extracted: 1. Clinical-pathological c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients treated at the UZ Brussel 2. Diagnosed in the period 2002-2015 3. Primary breast cancer 4. Histologically confirmed 5. Operable 6. Pre-treatment FDG-PET or PET/CT

Exclusion criteria

Exclusion criteria: 1. Previous history of cancer 2. Primary sarcoma of the breast 3. Palliative surgery for symptom control 4. No histopathological confirmation of cancer 5. Noninvasive carcinoma 6. Metastatic disease demonstrated by imaging modes other than FDG-PET

Design outcomes

Primary

Measure	Time frame
1. Overall survival up to 13 years after diagnosis assessed using patient medical records 2. Disease-free survival up to 13 years after diagnosis assessed using patient medical records	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Belgium

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026